PURPOSE. The purpose of this study was to elucidate the pathophysiological process in primary cultured corneal fibroblasts (PCFs) from normal subjects and granular corneal dystrophy (GCD) II patients, by using cDNA microarrays. METHODS. PCFs were isolated from the corneas of normal subjects and GCD II patients who were heterozygous and homozygous for the TGFBI R124H mutation. RNA was isolated from each sample, and gene expression profiles were analyzed with a cDNA microarray consisting of approximately 29,000 genes. Cell adhesion assays were performed to confirm the functionality of the detected gene expression profiles. RESULTS. Twofold differences were detected in the expression of 555 genes between wild-type and homozygous GCD II PCFs. Of these, 319 genes were upregulated, and 236 genes were downregulated in the homozygous GCD II PCFs. The most abundant and consistent changes were observed in gene families encoding signal transduction pathways involving the TGF-␤ receptor-and integrin-mediated signaling, cell differentiation and proliferation, immune responses, cell adhesion, extracellular matrix (ECM) proteolytic enzymes, cell cycle, cytoskeletal organization, mitochondrial energy metabolism, collagen catabolism, response to wounding, response to oxidative stress, and the ubiquitin-mediated proteasomal degradation pathway. Cell adhesion assays demonstrated that heterozygous and homozygous GCD II PCFs strongly attached to collagen-I, collagen-IV, fibronectin, and laminin, compared with wild-type cells. CONCLUSIONS. Alterations in the TGF-␤ receptor-and integrinmediated signaling pathway may play a key role in GCD II pathophysiology. If the novel factors identified in this study are involved in GCD II pathogenesis, they could assist in designing further studies to elucidate specific mechanisms of this disease.
G ranular corneal dystrophy II (GCD II) is a disorder characterized by age-dependent progressive accumulation of protein deposits in the corneal epithelia and stroma, followed by disruption of corneal transparency. GCD II is an autosomal dominant disorder caused by a point mutation (R124H) in the transforming growth factor-␤-induced gene (TGFBI) on chromosome 5, region q31.
1,2 TGFBI encodes a highly conserved 683 amino acid protein (TGFBIp) that contains a secretary signal sequence and an Arg-Gly-Asp (RGD) motif that serves as a ligand recognition site for integrins. 1 TGFBIp is a component of extracellular matrix (ECM) that mediates cell adhesion and migration by interacting with integrins. [3] [4] [5] More recently, it has been shown that loss of TGFBIp induces cell proliferation and spontaneous tumor development in TGFBI-knockout mice. 6 Thirty-eight different mutations in TGFBI are involved in corneal dystrophies. Remarkably, different mutations cause unique corneal dystrophy phenotypes, such as R124H in GCD II (also called Avellino corneal dystrophy), R124C in lattice corneal dystrophy type I, R555W in granular corneal dystrophy type I, and R555Q in Thiel-Behnke corneal dystrophy. 7 The cornea is an avascular tissue located in the anterior part of the eye and consists of five layers of tissue that serve as a barrier to infection. The principal cell types of the cornea include corneal epithelial cells in the outer region, keratocytes in the middle region, and endothelial cells in the inner region. Keratocytes, also known as corneal fibroblasts, have a dendritic morphology and produce keratan sulfate proteoglycans that are necessary for the maintenance of the corneal structure and physiology, particularly for the maintenance of corneal transparency. 8, 9 These cells are also responsible for the synthesis of collagen fibrils and the ECM and for stromal repair after injury or infection.
TGFBIp plays a significant role in the health of the cornea. For example, increased production of TGFBIp by corneal fibroblasts has been detected in areas of corneal injury, 10 and ablation of the corneal stroma by laser in situ keratomileusis (LASIK) in GCD II patients accelerates TGFBIp deposition. 11, 12 Overexpression of mutant TGFBI induces apoptotic cell death in human corneal epithelial cells, 13 and age-dependent retinal degeneration has been observed in transgenic mice that express a mutant form of the human TGFBI.
14 More recently, we have reported that PCFs are most susceptible to oxidative stress. 15 However, the pathophysiological process underlying GCD II has yet to be fully elucidated. To understand the pathophysiology of GCD II, we used cDNA microarray analysis to identify differential gene expression profiles between homozygous GCD II and wild-type PCFs. We also tested the ability of these cells to adhere to various ECM proteins to confirm the functional relevance of the gene expression results.
MATERIALS AND METHODS

Isolation and Culture of Primary Corneal Fibroblasts
Wild-type (n ϭ 3), heterozygous (n ϭ 3), and homozygous (n ϭ 3) primary human corneal fibroblasts were prepared by using a published method. 15 Donor confidentiality was maintained according to the Declaration of Helsinki, and the protocol was approved by Severance Hospital IRB Committee (CR04124), Yonsei University. GCD II was diagnosed by DNA sequencing analysis of TGFBI mutations. Age, sex, and diagnosis in the GCD II cases are shown in Table 1 . After removal of the corneal button for penetrating keratoplasty, the remaining corneal rims were harvested for culture of the normal corneal fibroblast. The medical records of the donors from the eye bank of Yonsei University Severance Hospital did not show any genetic or systemic metabolic disease. The fibroblasts grown from the pieces of corneal rims were treated as normal ones. Genetic normality of the BIGH3 gene in normal primary corneal fibroblasts was determined by DNA sequencing analysis. Table 1 presents information regarding the corneal fibroblasts used in these studies. For cDNA microarray analysis, six samples (normal sample pairs 1, 2, and 3; and homozygous sample pairs 1, 2, and 3) were analyzed, excluding the heterozygous sample. For RT-PCR studies, the samples were prepared by pooling total RNA from two samples ( Table 1 , pairs 1 and 2). The sample pairs 1 and 2 were used for Western blot analysis. For the cell adhesion assay, nine samples (normal, heterozygous, and homozygous sample pairs 1, 2, and 3) were analyzed.
RNA Extraction and Gene Expression Profiling
Transcriptional profiles were evaluated in three independent cell preparations, by using a cDNA microarray (GeneChip Human Gene 1.0 ST Array, GeneChip; Affymetrix, Santa Clara, CA) containing approximately 29,000 genes. To determine a variation and average changes (x-fold) in the expression of different genes in each sample and to compare these samples, we analyzed six samples (normal sample pairs 1, 2 and 3, and homozygous samples pair 1, 2, and 3) for new microarray analysis without total RNA pooling. Total RNA was extracted from the PCFs (TRIzol; Invitrogen, Carlsbad, CA) followed by purification (RNeasy kit; Qiagen, Valencia, CA) to remove residual DNA. The concentration of total RNA was determined by UV spectrophotometry (ND-1000 UV-Vis Spectrophotometer; Nanodrop Technologies, Wilmington, DE). Two quality controls were used for each RNA sample: (1) an A 260 /A 280 ratio between 1.7 and 2.3; and (2) an electropherogram showing two distinct ribosomal peaks corresponding to either 18S and 28S for eukaryotic RNA bands at a ratio of 28S/18S of Ͼ0.5 with minimal or no degradation. The arrays were scanned (GeneChip Scanner 3000 7G; Affymetrix), raw signal intensities were normalized (GeneChip Operating Software [GCOS] algorithm; Affymetrix), and the data were analyzed (Gene Chip DNA Analysis Software [GDAS], ver. 2.0 according to the Affymetrix GeneChip Expression Analysis Technical Manual; http://www.affymetrix.com). We detected a twofold change in differential gene expression between the normal and homozygous samples. For statistical data analysis, we used a two-tailed unpaired Student's t-test (P Ͻ 0.05), to assess significant differences between the two cell types.
Reverse Transcription-Polymerase Chain Reaction
Two micrograms of total RNA was reverse transcribed into cDNA (Superscript II reverse transcriptase; Invitrogen, Carlsbad, CA) and an Oligo (dT) primer (Invitrogen). The cDNA was amplified by using primers derived from the sequence of the selected differentially expressed genes, and ␤-actin expression was used as the control. Amplification products were visualized by electrophoresis in 1.2% agarose gels containing ethidium bromide. Specific RT-PCR primer sets and annealing temperatures are listed in Table 2 .
Preparation of Cell Lysates and Western Blot Analysis
Cell lysates were prepared in radio immunoprecipitation assay (RIPA) buffer (pH 7.4; containing a Complete Mini Protease Inhibitor Tablet; Roche Diagnostics, Indianapolis, IN). Crude cell lysates were centrifuged at 10,000g for 10 minutes at 4°C, to remove nuclear fragments and tissue debris. A portion of the supernatant was used to determine the total protein concentration with a bicinchoninic acid protein assay (BCA; Kit; Pierce, Rockford, IL), and equal amounts of each sample were analyzed by Western blot, as described previously. 15 The following antibodies were used: anti-integrin ␣ 2 (1:1000; Chemicon, Te- 
Cell-ECM Adhesion Profile Assays
Cell adhesion assays were performed using the ECM cell adhesion array kit (Cytomatrix; Chemicon International) according to the manufacturer's instructions. Nine samples (three samples for each of normal, heterozygous, and homozygous corneal fibroblast) were analyzed, and each experiment was repeated three times.
Statistical Analysis
Results were evaluated for significance (P Ͻ 0.05) with one-way ANOVA followed by Newman-Keuls multiple comparison tests. Results are expressed as the mean Ϯ SD (Prism ver. 4.0; Graph Pad Software Inc, San Diego, CA).
RESULTS
Gene Expression Profiles in Wild-Type and Homozygous GCD II PCFs
The GeneChip Human Gene 1.0 ST Array (Affymetrix) is a whole-transcript analysis chip composed of approximately 29,000 genes. To identify specific genes involved in the pathogenesis of GCD II, we compared the gene expression profiles between primary cultured wild-type and homozygous GCD II corneal fibroblasts. We detected twofold differences in the expression of 555 genes between these two cell types. Of these, 319 of these genes were upregulated and 236 were downregulated in the homozygous GCD II PCFs compared with wild-type ( Table 3) . Characterization of these genes into ontology groups suggests that GCD II-specific changes largely relate to changes in signal transduction (17%), cell cycle (13%), immune response (13%), cell adhesion (9%), cell differentiation (9%), cytoskeleton (9%), cell proliferation (6%), extracellular space (6%), cell-cell signaling (5%), response to wounding (5%), mitochondrion (2%), ubiquitin cycle (2%), endopeptidase activity (2%), TGF-␤ receptor signaling pathway (1%), integrin-mediated signaling pathway (1%), collagen (1%), and response to oxidative stress (1%) (Fig. 1) . Specific genes that were markedly upregulated were IFI44L (43. 
Differential Expression of ECM-Associated Genes
To confirm the ECM affinity data, we next tested the expression of proteins involved in ECM remodeling by Western blot (Figs. 2C, 2D ), as we expected that expression levels between wild-type, heterozygous, and homozygous GCD II PCFs would be different. We first investigated the expression patterns of collagen metabolism-related matrix metalloprotease (MMP)-1 and -2, because microarray assay profiles have shown a different expression of MMP-1 and -2. The protein levels of MMP-1 and -2 increased in heterozygous and homozygous GCD II compared with wild-type PCFs (Figs. 2C, 2D ). Expression level of integrin ␣ 2 , which is involved in collagen metabolism and cell adhesion, was also increased in heterozygous and homozygous GCD II PCFs. Furthermore, significantly increased protein levels of TGF-␤ receptors I, II, and III were observed in heterozygous and homozygous GCD II PCFs (Figs. 2C, 2D ). These results suggest that the disturbance of ECM metabolism, especially collagen metabolism, is a major factor leading to TGFBIp deposition in corneal ECM of GCD II.
Increased Affinities for ECM Substrates of GCD II PCFs
We detected altered expression of several ECM component genes (Table 3) in wild-type versus GCD II PCFs. As such, we hypothesized that the adhesive properties of GCD II PCFs may be different from those of wild-type PCFs. To test this, we investigated ECM adhesive properties of GCD II PCFs using an adhesion assay (Cytomatrix; Chemicon International), as described in Materials and Methods. The heterozygous and homozygous GCD II PCFs were more adhesive to collagen-I, collagen-IV, fibronectin, and lamine, than were the wild-type cells (Fig. 3 ).
DISCUSSION
In this study, cDNA microarray technology was used to compare the gene expression profiles of homozygous GCD II PCFs to that of wild-type cells, in an attempt to better understand a potential mechanism of GCD II disease. We detected at least a twofold change in expression of 555 genes and confirmed the relative expression levels of a select number of genes by RT-PCR and Western blot analysis. Finally, differences in the cell adhesion properties between GCD II and wild-type PCFs were detected, suggesting that disturbances in ECM-cell adhesion may play an important role in this disease.
Expression Levels of Genes Involved in the TGF-␤ Signaling Pathway
The TGF-␤ signaling pathway has been implicated as a regulator in numerous cellular and physiological processes including ECM homeostasis. 16 The expression of TGF-␤ in corneal fibroblast cultures also suggests that it plays a role in regulating ECM metabolism through the TGF-␤ signaling pathway. [17] [18] [19] TGF-␤ initiates signaling through a complex made up of TGF-␤ receptor (T␤R) I and T␤RII 20 and signals to the nucleus through the Smads protein. 21 Our results show that T␤RI, -II, and -III were upregulated in heterozygous and homozygous GCD II PCFs (Table 4 ). This suggests that TGFBIp expression may occur more rapidly in GCD II than in wild-type PCFs under various physiological conditions and could result in accelerated TGFBIp deposition and ultimate GCD II disease. Also, because overexpression of misfolded or mutant proteins could induce protein aggregation or deposition, increased T␤R expressions may play an important role in exacerbating GCD II pathogenesis. This idea is supported by previous studies in which GCD II was aggravated by TGF-␤ after LASIK surgery. 11, 12, 22 However, the specific mechanism(s) regarding the increase in T␤R expression in GCD II corneal fibroblasts remains unknown.
Differential Expression of Proteolytic Enzymes Involved in ECM Metabolism
T␤R-mediated signaling stimulates matrix deposition by promoting the expression of components of the ECM such as collagen and suppresses and/or activates proteolytic enzymes such as MMPs, which also degrade collagen. 23, 24 Previous studies have shown that expression of abnormal proteoglycan filaments and disruption in collagen organization were present among stromal TGFBIp deposits. 25 These studies suggest that altered ECM proteolytic enzyme activities affect TGFBIp deposits by degrading ECM molecules, by either scission of covalent bonds or cleavage of mutant TGFBIp. Several investigations suggest that abnormal proteolysis is involved in deposits of TGFBIp in the cornea of the TGFBI gene associated with corneal dystrophy. 26 This finding is consistent with the fact that amyloid precursor proteins associated with other amyloid diseases generally undergo proteolysis during amyloid generation. Such proteins include gelsolin in both lattice corneal dystrophy type I and Finnish-type familial amyloidosis, 27, 28 amyloid ␤ precursor protein in familial Alzheimer's disease, 29, 30 and BRI2 in familial British dementia. 31, 32 Our microarray data show differential expression of endopeptidaserelated genes such as serine-type endopeptidase activityrelated genes, serine-type endopeptidase inhibitor-related genes, aspartic-type endopeptidase activity, and metalloendopeptidase activity-related genes. Although ECM proteolytic enzymes such as MMPs for TGFBIp remain unidentified, our data suggest that proteolytic enzymes associated with ECM turnover may be involved in the generation of TGFBIp deposits in GCD II. Further studies are needed to identify specific proteolytic enzymes responsible for TGFBIp deposits in the cornea.
Cell Adhesion and Integrin Signaling
TGFBIp contains a domain rich in cysteine residues (EMI domain), four highly conserved fasciclin-like (FAS) domains, and a COOH-terminal Arg-Gly-Asp (RGD) motif. The presence of the FAS domains and the RGD motif suggests that TGFBIp may play a functional role in cell adhesion. More recently, it was found that TGFBIp plays an inhibitory role in the attachment of human scleral fibroblasts to collagen type I through interaction with both ␣v␤3 and ␣v␤5 integrin receptors. 33 In the present investigation, we showed that heterozygous and homozygous GCD II PCFs tightly attached to collagen-I, collagen-IV, fibronectin, and lamine, compared with wild-type cells. These results support those in previous studies that show that TGFBIp plays a functional role in cell-ECM adhesion in the corneal stroma. However, our data suggest that tight attachment of heterozygous and homozygous GCD II PCFs to some ECM molecules is not due to a direct interaction between TGFBIp and the ECM. There are at least two possible explanations for this observation. First, TGFBIp expression was not significantly different in the heterozygous GCD II, homozygous GCD II, and wild-type PCFs. 15 Second, although TGFBIp can bind to collagens I, II, and III 34 and to fibronectin, 35 mutations in the TGFBI that commonly occur in certain corneal dystrophies do not apparently affect its binding to type I collagen, fibronectin, and laminin. 36 It is possible that signaling through integrins is involved in the attachment of GCD II PCFs to the ECM, especially since TGFBIp directly interacts with integrins. 37 This possibility is supported by the fact that increased integrin ␣ 2 expression was detected in heterozygous and homozygous GCD II PCFs. Therefore, we suggest that increased cell adhesion does not result from structural changes, as a result of mutation, in the RGD motif and FAS domain of TGFBIp, but rather because of downstream signaling events that occur as a result of interactions between integrins and mutant TGFBIp.
In conclusion, our data suggest that the altered receptormediated signaling pathway of TGF-␤ and integrins play a key role in GCD II pathophysiology. This study also identified other novel factors involved in this process that could aid in the design of future experiments to further investigate the development of this disease. 
